6533b82ffe1ef96bd1294839
RESEARCH PRODUCT
Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention.
Carmelo CastellanaMichele CarellaGiuseppe CoppolaVincenzo SucatoSimona RasoSalvatore EvolaGiuseppe AndolinaEgle CorradoSalvatore NovoGiuseppina Novosubject
Malemedicine.medical_specialtyTicagrelorPrasugrelAdenosinemedicine.medical_treatmentTreatment outcomeMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicinemedicineHumansIn patient030212 general & internal medicineNon-ST Elevated Myocardial InfarctionAgedRetrospective Studiesbusiness.industryPercutaneous coronary interventionRetrospective cohort studyGeneral MedicineMiddle AgedNSTEMITreatment OutcomeEmergency medicineCardiologyPurinergic P2Y Receptor AntagonistsObservational studyFemalebusinessCardiology and Cardiovascular MedicineTicagrelorPrasugrelPrasugrel Hydrochloridemedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2017-06-01 | Journal of cardiovascular medicine (Hagerstown, Md.) |